Probiotics and prebiotics to combat enteric infections and HIV in the developing world: A consensus report

Marc Monachese, Susanna Cunningham-Rundles, Maria Alejandra Diaz, Richard Guerrant, Ruben Hummelen, Rober Kemperman, Marko Kerac, Remco Kort, Dan Merenstein, Pinaki Panigrahi, Balakrishnan Ramakrishna, Nasia Safdar, Andi Shane, Livia Trois, Gregor Reid

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Infectious disease in the developing world continues to represent one of the greatest challenges facing humanity. Every year over a million children suffer and die from the sequela of enteric infections, and in 2008 was estimated almost 2.7 million (UNAIDS 2009 update) adults and children became infected with human immunodeficiency virus (HIV). While oral rehydration therapy for diarrhea and antiretrovirals (ARV) for HIV are critical, there is a place for adjunctive therapies to improve quality of life. The importance of the human microbiota in retaining health is now recognized, as is the concept of replenishing beneficial microbes through probiotic treatments. Studies have shown that probiotics can reduce the duration of diarrhea, improve gut barrier function, help prevent bacterial vaginosis (BV) and enhance immunity even in HIV-infected subjects. However, many issues remain before the extent of probiotic benefits can be verified, and their application to the developing world realized. This consensus report outlines the potential probiotic, and to a lesser extent prebiotic, applications in resource disadvantaged settings, and recommends steps that could bring tangible relief to millions of people. The challenges to both efficacy and effectiveness studies in these settings include a lack of infrastructure and funding for scientists, students and research projects in developing countries; making available clinically proven probiotic and prebiotic products at affordable prices; and undertaking appropriately designed clinical trials. We present a roadmap on how efficacy studies may be conducted in a resource disadvantaged setting among persons with chronic diarrhea and HIV. These examples and the translation of efficacy into effectiveness are described.

Original languageEnglish (US)
JournalGut Microbes
Volume2
Issue number3
DOIs
StatePublished - Jan 1 2011

Fingerprint

Prebiotics
Probiotics
HIV
Diarrhea
Infection
Vulnerable Populations
Bacterial Vaginosis
Fluid Therapy
Microbiota
Developing Countries
Communicable Diseases
Immunity
Quality of Life
Clinical Trials
Students
Health
Therapeutics
Research

Keywords

  • Diarrhea
  • HIV/AIDS
  • Prebiotics
  • Probiotics
  • Resource disadvantaged
  • Roadmap

ASJC Scopus subject areas

  • Microbiology
  • Gastroenterology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Monachese, M., Cunningham-Rundles, S., Diaz, M. A., Guerrant, R., Hummelen, R., Kemperman, R., ... Reid, G. (2011). Probiotics and prebiotics to combat enteric infections and HIV in the developing world: A consensus report. Gut Microbes, 2(3). https://doi.org/10.4161/gmic.2.3.16106

Probiotics and prebiotics to combat enteric infections and HIV in the developing world : A consensus report. / Monachese, Marc; Cunningham-Rundles, Susanna; Diaz, Maria Alejandra; Guerrant, Richard; Hummelen, Ruben; Kemperman, Rober; Kerac, Marko; Kort, Remco; Merenstein, Dan; Panigrahi, Pinaki; Ramakrishna, Balakrishnan; Safdar, Nasia; Shane, Andi; Trois, Livia; Reid, Gregor.

In: Gut Microbes, Vol. 2, No. 3, 01.01.2011.

Research output: Contribution to journalArticle

Monachese, M, Cunningham-Rundles, S, Diaz, MA, Guerrant, R, Hummelen, R, Kemperman, R, Kerac, M, Kort, R, Merenstein, D, Panigrahi, P, Ramakrishna, B, Safdar, N, Shane, A, Trois, L & Reid, G 2011, 'Probiotics and prebiotics to combat enteric infections and HIV in the developing world: A consensus report', Gut Microbes, vol. 2, no. 3. https://doi.org/10.4161/gmic.2.3.16106
Monachese M, Cunningham-Rundles S, Diaz MA, Guerrant R, Hummelen R, Kemperman R et al. Probiotics and prebiotics to combat enteric infections and HIV in the developing world: A consensus report. Gut Microbes. 2011 Jan 1;2(3). https://doi.org/10.4161/gmic.2.3.16106
Monachese, Marc ; Cunningham-Rundles, Susanna ; Diaz, Maria Alejandra ; Guerrant, Richard ; Hummelen, Ruben ; Kemperman, Rober ; Kerac, Marko ; Kort, Remco ; Merenstein, Dan ; Panigrahi, Pinaki ; Ramakrishna, Balakrishnan ; Safdar, Nasia ; Shane, Andi ; Trois, Livia ; Reid, Gregor. / Probiotics and prebiotics to combat enteric infections and HIV in the developing world : A consensus report. In: Gut Microbes. 2011 ; Vol. 2, No. 3.
@article{2f23c184c85a4b0cbb7e8238fcfbe04f,
title = "Probiotics and prebiotics to combat enteric infections and HIV in the developing world: A consensus report",
abstract = "Infectious disease in the developing world continues to represent one of the greatest challenges facing humanity. Every year over a million children suffer and die from the sequela of enteric infections, and in 2008 was estimated almost 2.7 million (UNAIDS 2009 update) adults and children became infected with human immunodeficiency virus (HIV). While oral rehydration therapy for diarrhea and antiretrovirals (ARV) for HIV are critical, there is a place for adjunctive therapies to improve quality of life. The importance of the human microbiota in retaining health is now recognized, as is the concept of replenishing beneficial microbes through probiotic treatments. Studies have shown that probiotics can reduce the duration of diarrhea, improve gut barrier function, help prevent bacterial vaginosis (BV) and enhance immunity even in HIV-infected subjects. However, many issues remain before the extent of probiotic benefits can be verified, and their application to the developing world realized. This consensus report outlines the potential probiotic, and to a lesser extent prebiotic, applications in resource disadvantaged settings, and recommends steps that could bring tangible relief to millions of people. The challenges to both efficacy and effectiveness studies in these settings include a lack of infrastructure and funding for scientists, students and research projects in developing countries; making available clinically proven probiotic and prebiotic products at affordable prices; and undertaking appropriately designed clinical trials. We present a roadmap on how efficacy studies may be conducted in a resource disadvantaged setting among persons with chronic diarrhea and HIV. These examples and the translation of efficacy into effectiveness are described.",
keywords = "Diarrhea, HIV/AIDS, Prebiotics, Probiotics, Resource disadvantaged, Roadmap",
author = "Marc Monachese and Susanna Cunningham-Rundles and Diaz, {Maria Alejandra} and Richard Guerrant and Ruben Hummelen and Rober Kemperman and Marko Kerac and Remco Kort and Dan Merenstein and Pinaki Panigrahi and Balakrishnan Ramakrishna and Nasia Safdar and Andi Shane and Livia Trois and Gregor Reid",
year = "2011",
month = "1",
day = "1",
doi = "10.4161/gmic.2.3.16106",
language = "English (US)",
volume = "2",
journal = "Gut Microbes",
issn = "1949-0976",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Probiotics and prebiotics to combat enteric infections and HIV in the developing world

T2 - A consensus report

AU - Monachese, Marc

AU - Cunningham-Rundles, Susanna

AU - Diaz, Maria Alejandra

AU - Guerrant, Richard

AU - Hummelen, Ruben

AU - Kemperman, Rober

AU - Kerac, Marko

AU - Kort, Remco

AU - Merenstein, Dan

AU - Panigrahi, Pinaki

AU - Ramakrishna, Balakrishnan

AU - Safdar, Nasia

AU - Shane, Andi

AU - Trois, Livia

AU - Reid, Gregor

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Infectious disease in the developing world continues to represent one of the greatest challenges facing humanity. Every year over a million children suffer and die from the sequela of enteric infections, and in 2008 was estimated almost 2.7 million (UNAIDS 2009 update) adults and children became infected with human immunodeficiency virus (HIV). While oral rehydration therapy for diarrhea and antiretrovirals (ARV) for HIV are critical, there is a place for adjunctive therapies to improve quality of life. The importance of the human microbiota in retaining health is now recognized, as is the concept of replenishing beneficial microbes through probiotic treatments. Studies have shown that probiotics can reduce the duration of diarrhea, improve gut barrier function, help prevent bacterial vaginosis (BV) and enhance immunity even in HIV-infected subjects. However, many issues remain before the extent of probiotic benefits can be verified, and their application to the developing world realized. This consensus report outlines the potential probiotic, and to a lesser extent prebiotic, applications in resource disadvantaged settings, and recommends steps that could bring tangible relief to millions of people. The challenges to both efficacy and effectiveness studies in these settings include a lack of infrastructure and funding for scientists, students and research projects in developing countries; making available clinically proven probiotic and prebiotic products at affordable prices; and undertaking appropriately designed clinical trials. We present a roadmap on how efficacy studies may be conducted in a resource disadvantaged setting among persons with chronic diarrhea and HIV. These examples and the translation of efficacy into effectiveness are described.

AB - Infectious disease in the developing world continues to represent one of the greatest challenges facing humanity. Every year over a million children suffer and die from the sequela of enteric infections, and in 2008 was estimated almost 2.7 million (UNAIDS 2009 update) adults and children became infected with human immunodeficiency virus (HIV). While oral rehydration therapy for diarrhea and antiretrovirals (ARV) for HIV are critical, there is a place for adjunctive therapies to improve quality of life. The importance of the human microbiota in retaining health is now recognized, as is the concept of replenishing beneficial microbes through probiotic treatments. Studies have shown that probiotics can reduce the duration of diarrhea, improve gut barrier function, help prevent bacterial vaginosis (BV) and enhance immunity even in HIV-infected subjects. However, many issues remain before the extent of probiotic benefits can be verified, and their application to the developing world realized. This consensus report outlines the potential probiotic, and to a lesser extent prebiotic, applications in resource disadvantaged settings, and recommends steps that could bring tangible relief to millions of people. The challenges to both efficacy and effectiveness studies in these settings include a lack of infrastructure and funding for scientists, students and research projects in developing countries; making available clinically proven probiotic and prebiotic products at affordable prices; and undertaking appropriately designed clinical trials. We present a roadmap on how efficacy studies may be conducted in a resource disadvantaged setting among persons with chronic diarrhea and HIV. These examples and the translation of efficacy into effectiveness are described.

KW - Diarrhea

KW - HIV/AIDS

KW - Prebiotics

KW - Probiotics

KW - Resource disadvantaged

KW - Roadmap

UR - http://www.scopus.com/inward/record.url?scp=85046980179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046980179&partnerID=8YFLogxK

U2 - 10.4161/gmic.2.3.16106

DO - 10.4161/gmic.2.3.16106

M3 - Article

C2 - 21804356

AN - SCOPUS:85046980179

VL - 2

JO - Gut Microbes

JF - Gut Microbes

SN - 1949-0976

IS - 3

ER -